| Autor: |
Stefani MM; Department of Immunology, University Hospital, Federal University of Goias, Goiania, Brazil. stefani@internetional.com.br, Martelli CM, Morais-Neto OL, Martelli P, Costa MB, de Andrade AL |
| Jazyk: |
angličtina |
| Zdroj: |
International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association [Int J Lepr Other Mycobact Dis] 1998 Sep; Vol. 66 (3), pp. 356-64. |
| Abstrakt: |
The anti-phenolic glycolipid-I (PGL-I) assay as currently applied for leprosy is conceived as an early marker of asymptomatic infection, early disease diagnosis and cure monitoring. Its use as a prognostic marker of reaction is still a matter of controversy. We conducted a case-control study to investigate whether IgM and IgG anti-PGL-I antibodies could discriminate patients at increased risk of developing reactions. Eligible cases were untreated leprosy patients at the onset of type 1 and type 2 reactions recruited from among 600 concurrent, newly detected, untreated leprosy patients attending an outpatient clinic in central Brazil. For the patients with reaction, approximately the same number of leprosy cases without reaction matched as to bacterial index (BI), age and gender were randomly selected. Individuals without clinical leprosy were evaluated as healthy controls. Sera from type 1 reaction (N = 43) and type 2 reaction (N = 26) patients were tested by an ELISA using PGL-I synthetic disaccharide-BSA antigen and 1:300 sera dilution (cut-off point > or = 0.2 OD). Antibody profiles were evaluated by exploratory data analysis and reverse cumulative distribution curves. The IgG anti-PGL-I response did not have a defined pattern, being detected only at low levels. Our results indicate that leprosy patients, independently of their reactional status, produce high levels of IgM anti-PGL-I, demonstrating a strong correlation between the magnitude of antibody response and the BI. Patients with a higher BI were at least 3.4 times more prone to produce an antibody response compared to healthy controls. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
